Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib in BRAF Fusion-Positive Low-Grade Glioma or Pancreatic Cancer
NCT06159478Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2023
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib in glioma, pancreatic cancer (PC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Mar 2023; status: recruiting.
02
Drugs
binimetinib
03
Conditions
gliomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06159478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159478.